Isoniazid-induced alopecia in isoniazid-monoresistant pulmonary tuberculosis
Abstract
INTRODUCTION: Alopecia is a rare adverse reaction during tuberculosis (TB) treatment. Both drug-resistant TB and isoniazid (INH)-induced alopecia have been reported. We present this case because INH monoresistance coexisting with INH-induced alopecia has not previously been described in the literature. CASE: A 22-year-old woman was diagnosed with pulmonary TB and initiated on antituberculosis treatment (ATT). After 1 month, she developed sudden, severe hair loss. INH was suspected as the causative agent and discontinued. Hair regrowth was observed within 1 month. Drug resistance testing revealed INH monoresistance. Treatment was continued with rifampicin (R), pyrazinamide, ethambutol (E), and moxifloxacin for 2 months, followed by R and E for 7 months. CONCLUSION: Clinicians should be vigilant for alopecia in young female patients receiving ATT, as it may lead to treatment interruption for cosmetic reasons. Alopecia may also signal underlying drug resistance, and further studies are needed to establish biological evidence for this association.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.